Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ibcasertib - Chipscreen Biosciences

Next Previous
X
Search
Drug Profile

Ibcasertib - Chipscreen Biosciences

Alternative Names: Aurora B/VEGFR/PDGFR /c-Kit/CSF1R inhibitor; Chiauranib; Chiauranib - Chipscreen Biosciences; CS-2164; Ibcasertib

Latest Information Update: 18 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chipscreen Biosciences
  • Class Amides; Aniline compounds; Antineoplastics; Ethers; Naphthalenes; Quinolines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Aurora kinase B inhibitors; Macrophage colony-stimulating factor receptor antagonists; Mitosis inhibitors; Platelet-derived growth factor alpha receptor antagonists; Proto-oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ovarian cancer; Peritoneal cancer; Small cell lung cancer
  • Phase II Graft-versus-host disease; Non-Hodgkin's lymphoma; Soft tissue sarcoma; Triple negative breast cancer
  • Phase I/II Liver cancer
  • Preclinical Pancreatic cancer
  • No development reported Solid tumours

Most Recent Events

  • 09 Jul 2024 Chipscreen Biosciences plans a phase II trial for Adenocarcinoma (Late-stage disease, Metastatic disease, Combination therapy, First-line therapy, Inoperable/Unresectable) (PO) in August 2024 (NCT06492915)
  • 18 Mar 2024 Chipscreen Biosciences completes a clinical trial in Small cell lung cancer in China (PO) (NCT05371899)
  • 02 Jan 2024 Phase-II clinical trials in Graft-versus-host disease (PO) (Chipscreen Biosciences pipeline, January 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top